Kimberly Clark Corp vs Medtronic PLC — how do they compare? Kimberly Clark Corp trades at $97.59 (market cap $32.51B), while Medtronic PLC trades at $88.48 (market cap $112.24B). The key difference: Medtronic PLC is far larger — about 3.5× Kimberly Clark Corp's market cap, and Kimberly Clark Corp pays the higher dividend (5.24%). Which is the better fit depends on your goals — on Pluang, investors hold Kimberly Clark Corp for 93 Days and Medtronic PLC for 63 Days on average.
| KMB | MDT | |
|---|---|---|
Market Cap | $32.51B | $112.24B |
Volume | 6,139,913 | 105,663,236 |
Sector | Consumer Staples | Health |
52-Week High | $121.44 | $105.35 |
52-Week Low | $93.05 | $73.75 |
Typical Hold Time | 93 Days | 63 Days |
Enterprise Value | $38.07B | $131.58B |
Dividend Yield | 5.24% | 3.28% |
Signals from Pluang's Aura AI — not financial advice
Kimberly-Clark (KMB) trades at $97.74, up 1.31% on the day, with a bearish technical outlook and mixed fundamentals. Recent earnings show a Q2 2026 miss but beats in prior quarters, while revenue declined to $16.45B in 2025. The company maintains a strong dividend yield of over 5% with 54 consecutive years of increases, but cash flow trends raise sustainability questions amid its pending Kenvue acquisition.
KMB offers value with a P/E of 19.32 and analyst consensus target of $117.25, implying 20% upside, but risks include integration challenges from the Kenvue deal, litigation liabilities, and pressured cash flows. The stock's high ROE of 129.43% signals efficient capital use, yet investor sentiment is cautious due to near-term execution hurdles.
Medtronic (MDT) trades at $87.75, up 2.62% today, with strong analyst support (60.8% buy ratings) and a $97.80 consensus price target suggesting 11.5% upside. The stock shows consistent earnings beats in recent quarters and maintains a 49-year dividend growth streak. However, technical indicators signal bearish momentum with resistance near $89-90. Revenue growth accelerated to $33.54B in 2025 with net margins improving to 13.93%, though debt levels have risen to 31.1% of assets.
MDT presents a compelling value opportunity with attractive dividend yield and earnings momentum, but faces near-term technical headwinds and increasing leverage. The upcoming Q3 earnings report and MiniMed separation will be critical catalysts. Investors should weigh the strong fundamental recovery against bearish technical signals and monitor debt management closely.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →